Side-by-side comparison of AI visibility scores, market position, and capabilities
DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I led by Blackstone Growth; serves 7 of top 10 pharma and 8 of top 10 diagnostics companies.
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a secure, scalable, and regulatory-compliant cloud environment where pharmaceutical companies, genomics labs, biobanks, health systems, and research institutions can store, analyze, and share multimodal biomedical data — including genomic sequences, clinical records, imaging, and real-world evidence. The platform is purpose-built for the data types, compliance requirements, and computational workloads unique to biomedical research and precision medicine development.
Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones; rebranded Oct 2025 with new APEX platform for hyper-scalable virtual library screening.
Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core technology, AtomNet, is a convolutional neural network trained on vast datasets of protein-ligand interactions to predict binding affinity and drug-likeness at scale. In October 2025, Atomwise rebranded as Numerion Labs, reflecting a sharpened strategic focus on ultra-fast virtual screening and the development of its APEX platform for hyper-scalable chemical library screening — a capability validated in partnership with NVIDIA.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.